Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

IS THIS TRUE?...from SA I pm’d a number of yo

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154720
(Total Views: 709)
Posted On: 01/21/2021 9:26:11 AM
Posted By: SAF
IS THIS TRUE?...from SA

I pm’d a number of you about this...publicly people on this board took Nader’s side...and suddenly Bruce Patterson who was lionized became a hack that didn’t know what he was talking about...so...IS THIS CORRECT yes or no?

Some more details care of Dr. Patterson on twitter regarding the HIV BLA delay:
twitter.com/...
"Personally and knowing the FDA from the Maraviroc and Vicriviroc trials in the early 2000’s, I think they have questions about the tropism assay that qualifies a patient for CCR5 therapy. Tropism assays are highly variable and confounding."
And in response, "misiu 143" tweeted:
"When combo study was going on , there was no Receptor Occupancy Test .
It started sometimes second part of mono study...Why FDA is asking for it in combo after all this time , no one will know...IMO"
WHOA! I didn't know all this! These paint a whole DIFFERENT picture -- IF accurate. I mean, the tropism assay was NECESSARY to insure that the subject would, in fact, be susceptible to CCR5 blockade. So NOW Patterson is DISSING those assays as "highly variable and confounding"? Is that the problem that needs to be addressed? If correct, that could be a really BIG problem -- capable of overturning the entire trial.
And then the "misiu" tweet implies the issue is with the receptor occupancy test. That is just a means to determine the extent to which sufficient receptors are occupied so they will induce a significant decrease in viral load. Now with maraviroc, it was determined that "receptor occupancy close to the maximum is required to induce a significant decrease in viral load":
www.ncbi.nlm.nih.gov/...
And Cytodyn didn't even START to measure occupancy until SOME time in the mono trial? That sounds like it could take a LOT of work AND time if they need to make up the difference.


(5)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us